<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20250203151111&amp;utm_source=Chrome<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20250203151111&amp;utm_source=Chrome" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期一，2025年2月3日20:11:12 +0000</lastbuilddate><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>急性中风中针对神经元表面抗原的抗体：系统评价和荟萃分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/39897448/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250203151111&amp;v=2.18.0.post9+e462414<description>结论：中风患者的血清IgA/IgM NMDAR-ABS比对照组更频繁。由于几个方法论问题，应谨慎解释这些发现。还需要进行方法论上的其他研究，以阐明中风患者NMDAR-ABS的患病率和意义。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月17日； 16：1491880。 doi：10.3389/fimmu.2025.1491880。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：在急性中风患者（ASP）中，已经报道了针对神经元表面抗原（NSA-ABS）的抗体，特别是针对NMDA受体（NMDAR-AB）的抗体。但是，它们在中风中的作用远非被理解。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们进行了系统的综述和荟萃分析，以研究：1）与对照组相比，急性中风患者的NSA-ABS频率； 2）中风后NSA-ABS的<i>从头</i>出现； 3）它们对临床结果的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们在定性分析中包括了九项研究，在定量分析中包括了七项研究。由于缺乏有关其他NSA-ABS的数据，分析仅限于NMDAR-ABS。考虑到仅采用基于细胞测定法的研究，在急性中风患者（OR 2.69，95％CI 2.00-3.62，I <sup>2</sup> = 4％）中发现IGA-IGM NMDAR-ABS同种型（但未发现IgG）的频率更高。 。中风后没有<i>从头</i>nmdar-abs形成。平均排放/第7天NIHSS（SMD 0.21，95％CI -1.10-1.52，I2 = 84％）和3-12个月MRS（SMD 0.38，95％CI -0.56-1.32，I2，I2，I2，I2 = 78％）在有和没有NMDAR-ABS血清阳性的患者之间。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：中风患者的血清IgA/IgM NMDAR-ABS比对照组更频繁。由于几个方法论问题，应谨慎解释这些发现。还需要进行方法论上的其他研究，以阐明中风患者NMDAR-ABS的患病率和意义。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">系统审查注册：https：//www.crd.york.ac.uk/prospero/display_record.php?id=crd 42022241278#:~: text=httpspps%3a// display_record.php％3FID％3DCRD42022241278，标识符CRD42022241278。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39897448/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39897448</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11782032/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11782032</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1491880>10.3389/fimmu.2025.1491880</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39897448</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Matteo Paolucci</dc:creator><dc:creator>安德里亚·齐尼（Andrea Zini）</dc:creator><dc:creator>卢阿娜·莫雷利（Luana Morelli）</dc:creator><dc:creator> Rocco Liguori</dc:creator><dc:creator>玛丽亚·皮亚·吉安诺卡罗（Maria Pia Giannoccaro）</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>急性中风中针对神经元表面抗原的抗体：系统评价和荟萃分析</dc:title><dc:identifier>PMID：39897448</dc:identifier><dc:identifier> PMC：PMC11782032</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1491880</dc:identifier></item><item><title>亚临床和临床乳腺炎之前和期间，人牛奶的免疫学组成</title><link/>https://pubmed.ncbi.nlm.nih.gov/39896819/？<description>乳腺炎是一种影响超过25％的母乳喂养女性的炎症状况，通常与牛奶分泌，疼痛和不适有关，这通常会导致早期停止母乳喂养。尽管乳腺炎的病因是多因素的，但乳腺的促炎状态可能是危险因素。然而，乳脂成分的变化，特别是在乳腺炎之前和期间乳腺免疫特征的变化尚未得到很好的描述。帮助关闭这... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月17日； 15：1532432。 doi：10.3389/fimmu.2024.1532432。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">乳腺炎是一种影响超过25％的母乳喂养女性的炎症状况，通常与牛奶分泌，疼痛和不适有关，这通常会导致早期停止母乳喂养。尽管乳腺炎的病因是多因素的，但乳腺的促炎状态可能是危险因素。然而，乳脂成分的变化，特别是在乳腺炎之前和期间的牛奶免疫特征的变化尚未得到很好的描述。为了帮助缩小这一研究差距，我们记录了10名经历临床（CM）的乳房产生的牛奶的免疫特征，以及在征兆/症状发育的一周以及一周和一周和一周的临床（SCM）乳腺炎中患有亚临床（SCM）乳腺炎将它们与14个健康对照组生产的牛奶进行了比较。 CM被定义为具有乳腺炎的体征/症状，而SCM则假定如果参与者没有CM的征兆/症状，但是她的牛奶的体细胞计数>; 400,000 Cell/ml和/或钠到钾含量（NA） /k）比率>; 1.0。通过免疫测定法量化了36个免疫因子（包括免疫球蛋白，细胞因子，趋化因子和生长因子）的浓度。在诊断前一周，由开发CM的女性生产的牛奶具有明显的免疫特征，尤其是促炎性细胞因子IL-1β和调节性细胞因子IL-2，IL-4和IL-10的挤奶。相比之下，SCM女性产生的牛奶中的免疫特征与乳腺炎发作前一周的健康女性或患有CM的女性产生的免疫特征没有差异。一旦乳腺炎出现，CM和SCM组都观察到牛奶免疫特征的明显变化。 CM的特征是浓度升高的27种化合物，包括促炎性细胞因子（IL-1β，IL-1RA和TNFα）和趋化因子（包括IL-8，Eotaxin，IP-10，MCP-1，MIP1α和MIP1α和MIP1β） ，与健康对照相比。与健康对照组相比，牛奶在SCM期间的免疫特征是中间的，显示出更高水平的IL-6，IFNγ和MCP-1，这表明与CM相比，更温和，更受控的免疫反应。仅由乳腺炎影响的乳腺产生的牛奶改变了免疫谱。需要进一步的研究来确定在症状发作之前，是否可以使用牛奶免疫特征的这些差异来改善乳腺炎风险预测。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39896819/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896819</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11782115/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11782115</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1532432>10.3389/fimmu.2024.1532432</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39896819</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Irma Castro-Navarro</dc:creator><dc:creator>瑞安·M·佩斯（Ryan M Pace）</dc:creator><dc:creator>珍妮特·威廉姆斯</dc:creator><dc:creator>克里斯蒂娜DW的步伐</dc:creator><dc:creator>Harpreet Kaur</dc:creator><dc:creator>朱莉娅·皮亚斯科夫斯基（Julia Piaskowski）</dc:creator><dc:creator>阿尔贝托·阿拉贡（AlbertoAragón）</dc:creator><dc:creator>胡安·罗德里格斯（Juan MRodríguez）</dc:creator><dc:creator>标记麦奎尔</dc:creator><dc:creator>莱昂尼斯·费尔南德斯（Leonides Fernandez）</dc:creator><dc:creator> Michelle K McGuire</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>亚临床和临床乳腺炎之前和期间，人牛奶的免疫学组成</dc:title><dc:identifier>PMID：39896819</dc:identifier><dc:identifier> PMC：PMC11782115</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1532432</dc:identifier></item><item><title>评估糖尿病对单核细胞与淋巴细胞比的影响和量化量子 -  -TB金和结核病治疗监测的测定：一项前瞻性队列研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/39896818/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250203151111&amp;v=2.18.0.post9+e462414<description>糖尿病（DM）是活跃结核病（TB）发展的重要危险因素。 Quantiferon-TB Gold Plus（QFT-P），白细胞计数（WBC）测定法和单核细胞与淋巴细胞比率（MLR）反映了与TB相关的炎症反应，并提供了监测TB治疗的潜力，以更好地管理疾病。这项研究的目的是评估DM对QFT-P和WBC分析的各自性能的影响，以监测... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月17日； 15：1451046。 doi：10.3389/fimmu.2024.1451046。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">糖尿病（DM）是活跃结核病（TB）发展的重要危险因素。 Quantiferon-TB Gold Plus（QFT-P），白细胞计数（WBC）测定法和单核细胞与淋巴细胞比率（MLR）反映了与TB相关的炎症反应，并提供了监测TB治疗的潜力，以更好地管理疾病。这项研究的目的是评估DM对QFT-P和WBC分析在其能力中的各自性能的影响，以监测对药物敏感的肺结核（TBP）的治疗。在纳入时（D0），治疗结束时（M6）和治疗结束后的两个月（M8）的结核病患者（M8），将QFT-P和WBC进行了前瞻性比较。在实验室测量糖化血红蛋白（HBA1C）之后，将患者分为两组：TBP（n = 43）和TBDM（n = 30）组。与TBP组相比，TBDM患者的特征是结核分枝<i>杆菌</i>特异性QFT-P IFN-γ反应（分别为P &lt;0.001和P &lt;0.05，TB1和TB2抗原刺激后P &lt;0.001和P &lt;0.05）。与TBP组相比，在TBD组中观察到QFT-P检验的比例明显更高（91.3％vs 64.1％）在治疗结束时（P = 0.03）。 MLR分析显示，糖尿病和非糖尿病性结核病患者TB治疗后MLR值降低（P &lt;0.001和P &lt;0.05）。这些数据反映在用于监测结核病治疗的基于免疫宿主的测试中，似乎进一步表明，具有DM伴随的TB与结核病治疗后持续的炎症反应有关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39896818/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896818</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11782029/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11782029</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1451046>10.3389/fimmu.2024.1451046</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39896818</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Paulo Ranaivomanana</dc:creator><dc:creator> Arimanitra razafimahefa</dc:creator><dc:creator> Mame Ndiaye</dc:creator><dc:creator> crisca razafimahatratra</dc:creator><dc:creator> Haja Ramamonjisoa</dc:creator><dc:creator> Perlinot Herindrainy</dc:creator><dc:creator> Mamy Raherison</dc:creator><dc:creator> Antso Hasina Raherinandrasana</dc:creator><dc:creator> Julio Rakotonirina</dc:creator><dc:creator>乔纳森·霍夫曼（Jonathan Hoffmann）</dc:creator><dc:creator> Rila Ratovoson</dc:creator><dc:creator> Niaina rakotosamimanana</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>评估糖尿病对单核细胞与淋巴细胞比的影响和量化量子 -  -TB金和结核病治疗监测的测定：一项前瞻性队列研究</dc:title><dc:identifier>PMID：39896818</dc:identifier><dc:identifier> PMC：PMC11782029</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1451046</dc:identifier></item><item><title>对骨肉瘤免疫微环境和免疫疗法的机制的新见解</title><link/>https://pubmed.ncbi.nlm.nih.gov/39896817/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250203151111&amp;v=2.18.0.post9+e462414<description>骨肉瘤是一种恶性骨肿瘤，主要影响青少年，预后较差。虽然手术和化疗改善了局部病例的生存率，但肺转移将生存率显着降低到约20％，突显了对新治疗的需求。免疫疗法利用免疫系统靶向骨肉瘤细胞，显示出希望。这篇综述总结了骨肉瘤的生物学特征，肺的机制... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月17日； 15：1539696。 doi：10.3389/fimmu.2024.1539696。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">骨肉瘤是一种恶性骨肿瘤，主要影响青少年，预后较差。虽然手术和化疗改善了局部病例的生存率，但肺转移将生存率显着降低到约20％，突显了对新治疗的需求。免疫疗法利用免疫系统靶向骨肉瘤细胞，显示出希望。这篇综述总结了骨肉瘤的生物学特征，肺转移的机制和肿瘤免疫微环境（TME）。它涉及最近的免疫疗法进展，包括单克隆抗体，肿瘤疫苗，免疫细胞疗法，检查点抑制剂和溶瘤病毒，并讨论将这些病毒与标准疗法结合在一起。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39896817/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896817</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11782189/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11782189</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1539696>10.3389/fimmu.2024.1539696</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39896817</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator>康卢</dc:creator><dc:creator>Xingxing Min</dc:creator><dc:creator>张张</dc:creator><dc:date>2025-02-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>对骨肉瘤免疫微环境和免疫疗法的机制的新见解</dc:title><dc:identifier>PMID：39896817</dc:identifier><dc:identifier> PMC：PMC11782189</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1539696</dc:identifier></item><item><title>通过免疫检查点抑制剂治疗的恶性黑色素瘤患者循环肿瘤DNA的预后价值：系统评价和荟萃分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/39896816/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250203151111&amp;v=2.18.0.post9+e462414<description>结论：该荟萃分析表明，在接受ICI治疗的MM患者中，可检测和高水平的ctDNA与OS和PFS较差显着相关。因此，ctDNA可以在治疗前用作诊断和分层工具，也可以作为监测治疗反应和疾病进展的有效指标。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月17日； 15：1520441。 doi：10.3389/fimmu.2024.1520441。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：循环肿瘤DNA（CTDNA）是恶性黑色素瘤（MM）中新兴的生物标志物，高水平的ctDNA可能反映出较高的肿瘤负荷。但是，其对接收免疫检查点抑制剂（ICI）的MM的预后价值仍然有争议。这项荟萃分析旨在阐明ctDNA在该患者人群中的预后意义。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们对PubMed，Cochrane库，CNKI和EMBASE数据库进行了全面搜索，其中包括发布至2024年8月15日的研究，以研究CTDNA对ICI治疗的MM患者的预后影响。使用固定效应模型，我们系统地评估了CTDNA水平和关键存活结果之间的关联，包括总生存率（OS）和无进展生存率（PFS）。此外，还采用了漏斗图，贝格测试和Egger的测试来评估潜在的出版偏见。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：包括十一篇文章的十二项研究，涉及1063名接受ICI治疗的合格MM患者。结果表明，启动ICI治疗前可检测到CTDNA的患者的OS明显较差（HR = 3.19，95％CI = 2.22-4.58，P &lt;0.001）和PFS（HR = 2.08，95％CI = 1.61-2.69，P &lt;1.61-2.69，p &lt; 0.001）。此外，治疗过程中CTDNA的可检测性也与OS较差（HR = 4.57，95％CI = 3.03-6.91，P &lt;0.001）和PFS（HR = 3.79，95％CI = 2.13-6.75，P &lt;0.001，P &lt;0.001，P &lt;0.001，P &lt;0.001，P &lt;0.001 ）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：该荟萃分析表明，在接受ICI治疗的MM患者中，可检测和高水平的ctDNA与OS和PFS较差显着相关。因此，ctDNA可以在治疗前用作诊断和分层工具，也可以作为监测治疗反应和疾病进展的有效指标。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">系统评价注册：www.inplasy.com，标识符INPLASY2024110018。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39896816/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896816</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11782251/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11782251</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1520441>10.3389/fimmu.2024.1520441</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39896816</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Lei Liu</dc:creator><dc:creator> Shufu Hou</dc:creator><dc:creator> aiping Zhu</dc:creator><dc:creator> Bing Yan</dc:creator><dc:creator> Linchuan li</dc:creator><dc:creator>丹丹（Dandan）的歌</dc:creator><dc:date>2025-02-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>通过免疫检查点抑制剂治疗的恶性黑色素瘤患者循环肿瘤DNA的预后价值：系统评价和荟萃分析</dc:title><dc:identifier>PMID：39896816</dc:identifier><dc:identifier> PMC：PMC11782251</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1520441</dc:identifier></item><item><title>质量细胞仪：探索过去14年中系统性自身免疫和炎症性疾病的免疫景观</title><link/>https://pubmed.ncbi.nlm.nih.gov/39896815/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign = Journals&amp;utm_campaign = Journals&amp;utm_content = 101560960&amp;fc=none间<description>自身免疫性和炎症性疾病的临床表现和预后是异质的，即使在患有相同病理学的个体中也是如此。了解其发病机理所涉及的免疫学改变为不同的临床表型和治疗反应提供了宝贵的见解。免疫表型可能会导致诊断，监测，初始治疗决策以及自身免疫性和炎症性疾病的随访。大量的... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月17日； 15：1509782。 doi：10.3389/fimmu.2024.1509782。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">自身免疫性和炎症性疾病的临床表现和预后是异质的，即使在患有相同病理学的个体中也是如此。了解其发病机理所涉及的免疫学改变为不同的临床表型和治疗反应提供了宝贵的见解。免疫表型可能会导致诊断，监测，初始治疗决策以及自身免疫性和炎症性疾病的随访。质量细胞仪可在单细胞分辨率下测量40多个同时的细胞参数，因此具有评估复杂细胞系统和高维单细胞分析的巨大潜力。质量细胞术的高维度可更好地覆盖免疫种群动力学，并且与流式细胞仪相比，具有足够的能力来识别稀有细胞类型。在这篇全面的综述中，我们探讨了过去十年来质量细胞仪发现如何对参与系统性自身免疫和自身炎症性疾病的细胞参与者进行更深入的了解，并具有各自的治疗和预后影响。我们还深入研究了应用于质量细胞仪的生物信息学方法，以分析产生的大量数据，以及使用互补的单细胞RNA测序及其空间方式的使用的影响。我们的分析强调了一个事实，即质量细胞术捕获了有关细胞群体的主要信息，从而提供了有关自身免疫性疾病复杂发病机理的见解。未来的研究设计可能包括与其他 - 组合相关的质量细胞术发现，以使患者在适当的治疗臂上分层，并在自动免疫和炎症性疾病领域提供个性化疗法的进步。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39896815/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896815</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11782038/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11782038</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1509782>10.3389/fimmu.2024.1509782</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39896815</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> AïchaKante</dc:creator><dc:creator> Mathieu F Chevalier</dc:creator><dc:creator>达米安·塞恩（DamienSène）</dc:creator><dc:creator>珍妮·乔菲尔（Jeanne Chauffier）</dc:creator><dc:creator> StéphaneMouly</dc:creator><dc:creator>本杰明·格伦·切斯特曼</dc:creator><dc:creator>费里尔·阿齐巴尼（FérielAzibani）</dc:creator><dc:creator>本杰明梗</dc:creator><dc:creator>ThéoPezel</dc:creator><dc:creator> CloéComarmond</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>质量细胞仪：探索过去14年中系统性自身免疫和炎症性疾病的免疫景观</dc:title><dc:identifier>PMID：39896815</dc:identifier><dc:identifier> PMC：PMC11782038</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1509782</dc:identifier></item><item><title>阐明循环免疫细胞与特发性肺纤维化之间的因果关系和机制：孟德尔随机和转录组学的新见解</title><link/>https://pubmed.ncbi.nlm.nih.gov/39896814/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250203151111&amp;v=2.18.0.post9+e462414<description>结论：我们的研究通过遗传方法证明了特定免疫细胞表型与IPF的因果关系，并通过生物信息学分析将CTSB，IL10和AGER鉴定为IPF的生物标志物。这些发现为未来的临床和基础研究提供了指导。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月17日； 15：1437984。 doi：10.3389/fimmu.2024.1437984。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：越来越多的证据表明，循环免疫细胞表型与特发性肺纤维化（IPF）之间存在关联。尽管研究试图阐明两者之间的因果关系，但有必要进一步阐明特定机制和因果关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：我们旨在通过转录组数据分析进行两样本的孟德尔随机分析（MR）分析，以阐明循环免疫细胞与IPF之间的因果关系并探索潜在的生物标志物。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们首先使用两样本MR分析探索了IPF和免疫细胞表型之间的双向因果关系。从公共可用数据库中获得了全基因组的关联研究数据。标准化的仪器变量筛选过程用于选择单核苷酸多态性（SNP）以包含在MR中。 IVW代表的五种方法用于评估因果效应。随后，将与IPF的转录组数据结合使用的SNP最终基因进行了多种生物信息学分析，例如计时器，WGCNA，功能富集分析，蛋白质 - 蛋白质相互作用分析和ROC，以识别IPF生物标志物。最后，使用单细胞分析来验证我们的发现。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：MR研究确定了27种与IPF因果关系的免疫细胞表型，其中20种与降低IPF的风险和7种有关的风险与风险增加有关。 <i>CTSB</i> （AUC = 0.98）， <i>IL10</i> （AUC = 0.83）和<i>AGER</i> （AUC = 0.87）被确定为IPF的有希望的生物标志物。单细胞分析显示，IPF组与健康对照组之间的CD14 <sup>+</sup> CD16 <sup>+</sup>单核细胞，CD16 <sup>+</sup>单核细胞和粒细胞单核细胞的差异。三个中心基因在IPF患者的三个免疫细胞亚群中高度表达。它强调了三个基因作为生物标志物的潜在可行性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的研究通过遗传方法证明了特定免疫细胞表型与IPF的因果关系，并通过生物信息学分析将<i>CTSB</i> ， <i>IL10</i>和<i>AGER</i>鉴定为IPF的生物标志物。这些发现为未来的临床和基础研究提供了指导。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39896814/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896814</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11782250/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11782250</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1437984>10.3389/fimmu.2024.1437984</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39896814</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator>韩阳</dc:creator><dc:creator>Xuanyu Wu</dc:creator><dc:creator> Xiang Xiao</dc:creator><dc:creator> Jajing Chen</dc:creator><dc:creator>小米Yu</dc:creator><dc:creator>温赵</dc:creator><dc:creator>Fei Wang</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>阐明循环免疫细胞与特发性肺纤维化之间的因果关系和机制：孟德尔随机和转录组学的新见解</dc:title><dc:identifier>PMID：39896814</dc:identifier><dc:identifier> PMC：PMC11782250</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1437984</dc:identifier></item><item><title> IgG4介导的食管癌三元淋巴样结构中的M2巨噬细胞极化：对免疫抑制的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/39896813/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250203151111&amp;v=2.18.0.post9+e462414<description>结论：IgG4和IL-10可能通过促进TLS内M2巨噬细胞的极化而导致食管癌的免疫抑制，这可能是治疗靶标。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月17日； 15：1497783。 doi：10.3389/fimmu.2024.1497783。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：我们以前的研究强调了免疫球蛋白G4（IgG4）在介导肿瘤微环境（TME）内的免疫抑制中的潜在作用。 TME中的三级淋巴结构（TLS）具有重要的免疫相关功能。这项研究旨在分析表达IgG4的细胞，调节性T细胞（TREG）和M2型巨噬细胞的分布特征，并阐明了食管癌中TLS内IgG4与M2巨噬细胞极化之间的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">对象：阐明TLS中IgG4，Treg细胞和M2巨噬细胞的分布，并评估IgG4对巨噬细胞极化的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：用多重免疫荧光分析食道癌组织，以确定B细胞，T细胞及其亚型的空间分布和密度。研究了TLS中IgG4和CD8+ T细胞之间的关系，以及白介素-10（IL-10）表达和Treg存在。比较患者和健康对照组之间的血清IgG4和IL-10水平。<i>在体外</i>，观察到IgG4对单核细胞分化为M2巨噬细胞的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：成熟TL中的IgG4密度与CD8+ T细胞成反比，表明潜在的免疫抑制作用（P &lt;0.05，*）。血清分析表明，与对照组相比，肿瘤患者的IgG4（P &lt;0.01，**）和IL-10（P &lt;0.0001，****）均显着升高，并且在肿瘤患者中呈正相关（**）。<i>体外</i>实验证实，IgG4单核细胞分化为M2巨噬细胞，有可能增强TLS中的免疫抑制表型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：IgG4和IL-10可能通过促进TLS内M2巨噬细胞的极化而导致食管癌的免疫抑制，这可能是治疗靶标。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39896813/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896813</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11782137/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11782137</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1497783>10.3389/fimmu.2024.1497783</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39896813</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator>王王</dc:creator><dc:creator>Jirui li</dc:creator><dc:creator> Yinghai Wang</dc:creator><dc:creator>杨陈</dc:creator><dc:creator>Weifeng Zhang</dc:creator><dc:creator> Xinyan Pan</dc:creator><dc:creator> chanjuan su</dc:creator><dc:creator> Ziteng Li</dc:creator><dc:creator>李王</dc:creator><dc:creator>江吉</dc:creator><dc:date>2025-02-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>IgG4介导的食管癌三元淋巴样结构中的M2巨噬细胞极化：对免疫抑制的影响</dc:title><dc:identifier>PMID：39896813</dc:identifier><dc:identifier> PMC：PMC11782137</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1497783</dc:identifier></item><item><title>肾功能受损的肾脏移植患者中VV116的严重代谢积累：病例系列报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/39896812/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250203151111&amp;v=2.18.0.post9+e462414<description> Covid-19在移植后个体中的治疗是具有挑战性的，这主要是由于Nirmatrelvir/Ritonavir和他克莫里木马斯之间的药物相互作用。 Deuremidevir Hydrobromide片剂（VV116）是一种口服的小分子剂靶向SARS-COV-2 RDRP，并抑制病毒复制。它可能存在药物相互作用的可能性很小，并且有可能提供新的治疗选择。我们描述了三例肾移植患者肾脏受损的患者... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月17日； 15：1501813。 doi：10.3389/fimmu.2024.1501813。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Covid-19在移植后个体中的治疗是具有挑战性的，这主要是由于Nirmatrelvir/Ritonavir和他克莫里木马斯之间的药物相互作用。 Deuremidevir Hydrobromide片剂（VV116）是一种口服的小分子剂靶向SARS-COV-2 RDRP，并抑制病毒复制。它可能存在药物相互作用的可能性很小，并且有可能提供新的治疗选择。我们描述了三例肾移植患者患有肾功能受损的肾功能受损，这些肾脏功能受损，他们患有19009肺炎，并接受了VV116治疗。尽管药物积累的程度不同，但这些患者仍可以快速病毒清除率，并迅速改善了肺炎症状。值得注意的是，克莫司血液浓度在整个治疗过程中保留在治疗范围内，尽管药物积累，但仍未观察到临床上的不良事件。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39896812/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896812</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11782228/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11782228</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1501813>10.3389/fimmu.2024.1501813</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39896812</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Jiaying Zhang</dc:creator><dc:creator> Yuan Gao</dc:creator><dc:creator>小苗</dc:creator><dc:creator>魏王</dc:creator><dc:creator>Zhongkai周</dc:creator><dc:creator>Yunyi Gao</dc:creator><dc:creator> Liwei Liu</dc:creator><dc:creator> Menghua Wu</dc:creator><dc:creator> KE MA</dc:creator><dc:creator>周周</dc:creator><dc:creator>阳阳</dc:creator><dc:creator>莎蒙</dc:creator><dc:creator>yingmei feng</dc:creator><dc:creator> Zhuorui Zhao</dc:creator><dc:creator> Wei Liu</dc:creator><dc:creator> Danlei Mou</dc:creator><dc:creator> Zixin Kang</dc:creator><dc:creator> Lianchun Liang</dc:creator><dc:creator>智吉·胡</dc:creator><dc:date>2025-02-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>肾功能受损的肾脏移植患者中VV116的严重代谢积累：病例系列报告</dc:title><dc:identifier>PMID：39896812</dc:identifier><dc:identifier> PMC：PMC11782228</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1501813</dc:identifier></item><item><title>评估供体肾功能：CIRBP在预测移植后延迟移植功能中的作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/39896811/？<description>结论：这项研究表明，供体等离子体CIRBP水平可以有效预测DGF的发生。 CIRBP是一种用于评估移植肾功能的潜在新型生物标志物。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月17日； 15：1518279。 doi：10.3389/fimmu.2024.1518279。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：延迟的移植功能（DGF）缩短了移植肾脏的存活时间，并增加了排斥的风险。当前方法在预测DGF方面不足。需要更精确的工具来评估肾脏适合移植。可冷诱导的RNA结合蛋白（CIRBP）表达与急性肾损伤有关，这表明其作为移植肾功能的新生物标志物的潜力。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们包括了已故的捐助者和接受者，他们在2016年至2019年之间成功进行了肾脏移植。接受者及其成对的捐赠者根据接受者的GRAFT肾功能的恢复，将DGF或立即移植功能（IGF）组分配给了DGF或立即移植功能（IGF）组。使用酶联免疫吸附测定试剂盒测量供体等离子体CIRBP水平，以评估其与DGF的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：DGF组中的供体等离子体CIRBP浓度约为IGF组中的两倍（6.82 vs. 3.44； P &lt;0.001）。在CIRBP浓度超过7.92 ng/mL的所有情况下，DGF发生。此外，单变量和多变量分析（优势比[OR] = 1.660; P &lt;0.001）证实供体等离子体CIRBP水平是DGF的独立危险因素。另外，CIRBP较高的水平与6个月时血浆肌酐增加有关（R²= 0.08; P &lt;0.001），生存分析显示DGF受体的肾脏存活率较短（P = 0.002）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究表明，供体等离子体CIRBP水平可以有效预测DGF的发生。 CIRBP是一种用于评估移植肾功能的潜在新型生物标志物。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验注册：https：//clinicaltrials.gov，标识符NCT06641622。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39896811/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896811</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11782215/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11782215</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1518279>10.3389/fimmu.2024.1518279</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39896811</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Qianghua leng</dc:creator><dc:creator>莫林·马</dc:creator><dc:creator>Zuofu Tang</dc:creator><dc:creator>魏江</dc:creator><dc:creator>Fei Han</dc:creator><dc:creator> Zhengyu黄</dc:creator><dc:date>2025-02-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>评估供体肾功能：CIRBP在预测移植后延迟移植功能中的作用</dc:title><dc:identifier>PMID：39896811</dc:identifier><dc:identifier> PMC：PMC11782215</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1518279</dc:identifier></item><item><title>治疗等离子体交换可加速严重的Covid-19中免疫细胞的恢复</title><link/>https://pubmed.ncbi.nlm.nih.gov/39896810/？<description>结论：因此，我们的结果表明，在标准治疗中添加TPE疗程会加速免疫细胞的恢复，并有助于某些严重COVID-COVID-19患者的适当抗病毒药T细胞反应的发展。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月17日； 15：1492672。 doi：10.3389/fimmu.2024.1492672。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：免疫学障碍（抗型I IFN自身抗体产生，细胞因子风暴，淋巴细胞减少症，T细胞过度激活和精疲力尽）导致严重的COVID-19感染期间疾病加剧。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这项研究中，我们建立了一项前瞻性，随机的临床试验（临床Trials.gov ID：NCT04751643），并在严重的Covid-19患者中进行了治疗性等离子体交换（TPE），以减少多余的细胞因子和自身抗体，并评估并评估并评估是否将TPE添加到标准处理中（ST，包括皮质类固醇加上高流量氧）都可以帮助恢复免疫参数并限制急性呼吸遇险综合征（ARDS）的进展。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：如预期的那样，进行TPE减少了抗型I IFN自身抗体的量，并改善了或限制了某些炎症介质（IL-18，IL-7，CCL2，CCL3等）的消除或限制的产生。与ST对照组相比，Covid-19患者的血液。有趣的是，尽管TPE在整个方案中不影响ARDS参数的变化，但事实证明，它比ST在逆转淋巴细胞减少症，防止T细胞过度激活和减少T细胞疲劳方面更有效，特别是在早期有利的TPE患者中结果。 TPE还恢复了适当数量的CD4+和CD8+ T细胞记忆群，并增加了这些患者循环病毒特异性T细胞的数量。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: Our results therefore indicate that the addition of TPE sessions to the standard treatment accelerates immune cell recovery and contributes to the development of appropriate antiviral T-cell responses in some patients with severe COVID-19 disease.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39896810/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896810</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11782122/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11782122</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1492672>10.3389/fimmu.2024.1492672</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39896810</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Aurelie Guironnet-Paquet</dc:creator><dc:creator> Hind Hamzeh-Cognasse</dc:creator><dc:creator> Frederic Berard</dc:creator><dc:creator> Fabrice Cognasse</dc:creator><dc:creator> Jean Christophe Richard</dc:creator><dc:creator> Hodane Yonis</dc:creator><dc:creator> Mehdi Mezidi</dc:creator><dc:creator> Olivier Desebbe</dc:creator><dc:creator> Bertrand Delannoy</dc:creator><dc:creator> Sophie Demeret</dc:creator><dc:creator> Clemence Marois</dc:creator><dc:creator> Samir Saheb</dc:creator><dc:creator> Quoc Viet Le</dc:creator><dc:creator> Mathieu Schoeffler</dc:creator><dc:creator> Paul Simon Pugliesi</dc:creator><dc:creator> Sophie Debord</dc:creator><dc:creator> Paul Bastard</dc:creator><dc:creator> Aurélie Cobat</dc:creator><dc:creator> Jean Laurent Casanova</dc:creator><dc:creator> Rémi Pescarmona</dc:creator><dc:creator> Sébastien Viel</dc:creator><dc:creator> Jean François Nicolas</dc:creator><dc:creator> Audrey Nosbaum</dc:creator><dc:creator> Marc Vocanson</dc:creator><dc:creator> Olivier Hequet</dc:creator><dc:date> 2025-02-03</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> Therapeutic plasma exchange accelerates immune cell recovery in severe COVID-19</dc:title><dc:identifier> pmid:39896810</dc:identifier><dc:identifier> pmc:PMC11782122</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1492672</dc:identifier></item><item><title> Integrative single-cell and bulk RNA-seq analyses identify CD4&lt;sup>;+&lt;/sup>; T-cell subpopulation infiltration and biomarkers of regulatory T cells involved in mediating the progression of atherosclerotic plaque</title><link/> https://pubmed.ncbi.nlm.nih.gov/39896809/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250203151111&amp;v=2.18.0.post9+e462414<description> CONCLUSION: Our results indicate that the transcription factors TEFC, IRF8, ZNF267, KLF2, and JUNB in Tregs could be potential targets for the clinical management of AS. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 17;15:1528475. doi: 10.3389/fimmu.2024.1528475. eCollection 2024.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Atherosclerosis (AS) is a chronic inflammatory disease with a significant contributor to mortality worldwide. Regulatory T cells (Tregs) are atheroprotective. However, the potential pathways and genes associated with atherosclerotic plaque progression in Tregs remain largely unknown. Therefore, this study aimed to identify critical target genes and pathways of Tregs associated with the progression of AS. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The gene expression data and single cell RNA-seq data of AS were downloaded from the Gene Expression Omnibus (GEO) database. Initially, we quantified CD4 <sup>+</sup> T cell proportions in non-plaque and plaque tissues using cell infiltration by estimation of RNA sequences (CIBERSORT) analysis, identifying pivotal transcription factors regulating the number of Tregs in atherosclerotic plaque. Subsequently, we identified significantly differential expressed genes of Tregs during the progression of atherosclerotic plaque and investigated the key pathways and transcription factors for these differentially expressed genes using gene ontology (GO) analysis and transcription factor enrichment analysis (TFEA), respectively. We also employed high dimensional weighted gene co-expression network analysis (hdWGCNA) and cell-cell communication analysis to elucidate the modules and cascade reaction of Tregs in the progression of AS. The key genes diagnostic potential was assessed via receiver operating characteristic (ROC) curve analysis. Finally, the target genes were validated in AS model using Ldlr <sup>-/-</sup> mice. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We found that the proportion of Tregs significantly decreased, and Th2 cells showed a significant increase in atherosclerotic plaque compared to that in non-plaque arterial tissues. The five transcription factors (TEFC, IRF8, ZNF267, KLF2, and JUNB), identified as key targets associated with the function and the number of Tregs driving the progression of AS, primarily regulate immune response, ubiquitination, cytokine production, and T-cell differentiation pathways. ZNF267 may mainly involve in regulating ubiquitination, TGF-beta, and MAPK pathways of Tregs to regulate the function and the number of Tregs during the progress of AS. Interestingly, we found that IRF8 and ZNF267 as potential biomarkers were upregulated in circulating CD4+ T cells in patients with atherosclerotic coronary artery disease. Moreover, we also found that the changes of the function and the number of Tregs could modulate endothelial cell and smooth muscle cell functions to counteract AS through ligand-receptor pairs such as the MIF signaling pathway. Finally, we validated that two of the five transcription factors were also upregulated in mice atherosclerotic plaque through AS model using Ldlr <sup>-/-</sup> mice. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: Our results indicate that the transcription factors TEFC, IRF8, ZNF267, KLF2, and JUNB in Tregs could be potential targets for the clinical management of AS.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39896809/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896809</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11781991/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11781991</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1528475>10.3389/fimmu.2024.1528475</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39896809</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Yifeng Zhang</dc:creator><dc:creator> Shuxian Lu</dc:creator><dc:creator> Liang Qiu</dc:creator><dc:creator> Manman Qin</dc:creator><dc:creator> Dan Shan</dc:creator><dc:creator> Lianhua Xie</dc:creator><dc:creator> Yao Yi</dc:creator><dc:creator> Jun Yu</dc:creator><dc:date> 2025-02-03</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> Integrative single-cell and bulk RNA-seq analyses identify CD4&lt;sup>;+&lt;/sup>; T-cell subpopulation infiltration and biomarkers of regulatory T cells involved in mediating the progression of atherosclerotic plaque</dc:title><dc:identifier> pmid:39896809</dc:identifier><dc:identifier> pmc:PMC11781991</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1528475</dc:identifier></item><item><title> Efficacy and safety of neoadjuvant chemoimmunotherapy and chemotherapy in patients with potentially resectable stage IIIA/IIIB NSCLC: a retrospective study</title><link/> https://pubmed.ncbi.nlm.nih.gov/39896808/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250203151111&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: NCI is more effective and safer for patients with potentially resectable stage IIIA/IIIB NSCLC. Compared with NC alone, NCI significantly improves the pathological response and DFS without increasing adverse events. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 17;15:1479263. doi: 10.3389/fimmu.2024.1479263. eCollection 2024.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Treatment of locally advanced unresectable non-small cell lung cancer (NSCLC) is a significant challenge, especially for patients with IIIA/IIIB NSCLC. Patients receiving neoadjuvant chemoimmunotherapy (NCI) show improved pathological responses and disease-free survival (DFS) compared to those receiving Neoadjuvant chemotherapy (NC). However, there is still no consensus on the treatment for potentially resectable stage IIIA/IIIB NSCLC. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This retrospective study included 71 patients newly diagnosed with stage III NSCLC at our institution between 2017 and 2023: 46 patients received NCI and 25 patients received NC followed by surgical resection. Their clinicopathological characteristics were reviewed and analyzed. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Patients who received NCI had a significantly longer DFS. The median DFS was 15 months in the NC group (hazard ratio: 0.186, 95% confidence interval[CI]: 0.073-0.479; <i>P</i> &lt;0.001) but had not been reached in the NCI group. The percentage of patients achieving a major pathologic response was 65.9% (29/44, 95% CI: 50.0%-79.1%) with NCI and 16.7% (4/24, 95% CI: 5.5%-38.2%) with NC alone( <i>P</i> &lt;0.001). The percentage of patients with pathologic complete response was 36.4% (16/44, 95% CI: 22.8%-52.3%) after NCI compared with 8.3% (2/24, 95% CI: 1.5%-28.5%) after NC ( <i>P</i> = 0.012). The survival curve shows that the overall survival for the NCI group has a better trend than that of the NC group, but there is no significant difference ( <i>P</i> =0.193). The incidence of all-grade adverse events was greater in the NCI group than in the NC group (80.4% vs. 64.0%). The incidence of grade ≥3 adverse events was 10.9% (n=5) and 8.0% (n=2), respectively; however, these differences were insignificant. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: NCI is more effective and safer for patients with potentially resectable stage IIIA/IIIB NSCLC. Compared with NC alone, NCI significantly improves the pathological response and DFS without increasing adverse events.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39896808/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896808</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11782129/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11782129</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1479263>10.3389/fimmu.2024.1479263</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39896808</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Yuchen Wang</dc:creator><dc:creator> Xiaobo Ma</dc:creator><dc:creator> Kewei Ma</dc:creator><dc:creator> Xi Chen</dc:creator><dc:creator> Hua He</dc:creator><dc:creator> Xiangye Zhao</dc:creator><dc:creator> Mengge Fan</dc:creator><dc:creator> Yinghui Xu</dc:creator><dc:date> 2025-02-03</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> Efficacy and safety of neoadjuvant chemoimmunotherapy and chemotherapy in patients with potentially resectable stage IIIA/IIIB NSCLC: a retrospective study</dc:title><dc:identifier> pmid:39896808</dc:identifier><dc:identifier> pmc:PMC11782129</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1479263</dc:identifier></item><item><title> Disulfidptosis-related gene signatures as prognostic biomarkers and predictors of immunotherapy response in HNSCC</title><link/> https://pubmed.ncbi.nlm.nih.gov/39896807/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250203151111&amp;v=2.18.0.post9+e462414<description> CONCLUSION: The prognostic model effectively predicts HNSCC outcomes, with better prognosis in the low-risk group. DSTN upregulation promotes tumor growth, and its knockout inhibits proliferation, migration, and invasion. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 17;15:1456649. doi: 10.3389/fimmu.2024.1456649. eCollection 2024.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Disulfidptosis is a newly discovered form of cell death associated with tumorigenesis, particularly under oxidative stress and metabolic disorder conditions. Currently, the biological mechanisms of disulfidptosis-related genes (DRGs) in head and neck squamous cell carcinoma (HNSCC) remain unclear. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The study includes sections on methodologies, data sources, clinical data collection, subtype establishment, identification and analysis of differentially expressed genes, genetic variation, and the construction and validation of a DRG prognostic model. Various analyses are conducted, including the relationship between the risk scores model and clinicopathological features, immune status, immune checkpoints, tumor mutational burden (TMB), microsatellite instability (MSI), ESTIMATE, mRNAsi, and drug sensitivity. The study also covers single-cell analysis and DNA methylation analysis of DRGs, and the prediction of potential microRNA and long non-coding RNA target genes. Prognostic DRGs expression in HNSCC is validated through RT-qPCR and immunohistochemistry. The model&#39;s predictive capability is confirmed using external validation cohorts from GEO datasets and clinical tissue samples. The role of DSTN in HNSCC is further validated through gene knockout experiments. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We identified four valuable genes (SLC3A2, NUBPL, ACTB, DSTN) and constructed a prognostic model, along with identifying two DRG-related subtypes. Analysis of the DRG risk score revealed that the low-risk group had a better prognosis compared to the high-risk group. Significant correlations were found between the DRG risk score and clinical features, immunotherapy response, drug sensitivity, and genes related to RNA epigenetic modifications. Low-risk HNSCC patients were identified as potential beneficiaries of immune checkpoint inhibitor (ICI) therapy. A regulatory axis involving DSTN, hsa-miR-181c-5p, LUCAT1, and IGFL2-AS1 was constructed for HNSCC. RT-qPCR and IHC data further validated the upregulation of prognostic DRGs in HNSCC. The prognostic model demonstrated excellent predictive performance for the prognosis of HNSCC patients. Additionally, DSTN was significantly overexpressed in tumor cells; its knockdown inhibited tumor cell proliferation, migration, and invasion. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: The prognostic model effectively predicts HNSCC outcomes, with better prognosis in the low-risk group. DSTN upregulation promotes tumor growth, and its knockout inhibits proliferation, migration, and invasion.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39896807/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896807</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11782277/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11782277</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1456649>10.3389/fimmu.2024.1456649</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39896807</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Haotian Qin</dc:creator><dc:creator> Juan Xu</dc:creator><dc:creator> Yaohang Yue</dc:creator><dc:creator> Meiling Chen</dc:creator><dc:creator> Zheng Zhang</dc:creator><dc:creator> Panpan Xu</dc:creator><dc:creator> Yan Zheng</dc:creator><dc:creator> Hui Zeng</dc:creator><dc:creator> Jian Weng</dc:creator><dc:creator> Jun Yang</dc:creator><dc:creator> Fei Yu</dc:creator><dc:date> 2025-02-03</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> Disulfidptosis-related gene signatures as prognostic biomarkers and predictors of immunotherapy response in HNSCC</dc:title><dc:identifier> pmid:39896807</dc:identifier><dc:identifier> pmc:PMC11782277</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1456649</dc:identifier></item><item><title> High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer &lt;em>;in vitro&lt;/em>; and &lt;em>;in vivo&lt;/em>; models</title><link/> https://pubmed.ncbi.nlm.nih.gov/39896806/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250203151111&amp;v=2.18.0.post9+e462414<description> INTRODUCTION: Immune checkpoint inhibitors(ICIs) targeting programmed cell death protein 1 (PD1) confer significant survival benefits to patients with non-small cell lung cancer (NSCLC). However, there remains a substantial unmet need to identify therapeutic approaches to overcome resistance and provide benefits to these patients. High-dose ascorbic acid (AA) acts synergistically with many standard anticancer treatments. However, little is known about the effect of high-dose AA on improving the... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 17;15:1512605. doi: 10.3389/fimmu.2024.1512605. eCollection 2024.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTRODUCTION: Immune checkpoint inhibitors(ICIs) targeting programmed cell death protein 1 (PD1) confer significant survival benefits to patients with non-small cell lung cancer (NSCLC). However, there remains a substantial unmet need to identify therapeutic approaches to overcome resistance and provide benefits to these patients. High-dose ascorbic acid (AA) acts synergistically with many standard anticancer treatments. However, little is known about the effect of high-dose AA on improving the efficacy of anti-PD1 inhibitors in NSCLC. This study aimed to elucidate the effects of high-dose AA on anti-PD1 immunotherapy in NSCLC. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The combined effects of high-dose AA and anti-PD1 were investigated using a coculture model of H460 cells and CD8+ T cells and an LLC1 lung cancer syngeneic mouse model. To investigate the molecular mechanism, tumor tissues from mice were analyzed by comprehensive proteomic profiling using nano-LC-ESI-MS/MS. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Pretreatment with a high dose of AA led to enhanced the sensitivity to the cytotoxicity of CD8+ T cells derived from healthy donor for H460 cells. Additionally, the combination of anti-PD1 and high-dose AA significantly increased CD8+ T cell cytotoxicity in H460 cells. The combination of anti-PD1 and high-dose AA showed dramatic antitumor effects in a syngeneic mouse model of lung cancer by significantly reducing tumor growth and increasing CD8+ T cell-dependent cytotoxicity and macrophage activity. Comprehensive protein analysis confirmed that high-dose AA in anti-PD1-treated tumor tissues enhanced the antitumor effects by regulating various immune-related mechanisms, including the B cell and T cell receptor signaling pathways, Fc gamma R-mediated phagocytosis, and natural killer (NK) cell-mediated cytotoxicity. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DISCUSSION: Our results suggest that high-dose AA may be a promising adjuvant to potentiate the efficacy of anti-PD1 immunotherapy.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39896806/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">39896806</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11783322/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250203151111&v=2.18.0.post9+e462414">PMC11783322</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1512605>10.3389/fimmu.2024.1512605</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39896806</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Hak Su Kim</dc:creator><dc:creator> Seung-Hyun Kwon</dc:creator><dc:creator> Ok Kyung Choi</dc:creator><dc:creator> Taekyu Lim</dc:creator><dc:date> 2025-02-03</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer &lt;em>;in vitro&lt;/em>; and &lt;em>;in vivo&lt;/em>; models</dc:title><dc:identifier> pmid:39896806</dc:identifier><dc:identifier> pmc:PMC11783322</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1512605</dc:identifier></item></channel></rss>